Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 2/20 | 0.58 |
| ▸ | JAK3 | P52333 | 1/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.55 |
| ▸ | CDK4 | P11802 | 8/20 | 0.54 |
| ▸ | CCND1 | P24385 | 7/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.54 |
| ▸ | CDK9 | P50750 | 1/20 | 0.54 |
| ▸ | CCND2 | P30279 | 6/20 | 0.53 |
| ▸ | CCND3 | P30281 | 6/20 | 0.53 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.53 |
| ▸ | CDK2 | P24941 | 3/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.53 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.53 |
| ▸ | CDK1 | P06493 | 2/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.53 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30346164 | 1.00 | TNK2 (0.58) | TNK2JAK3JAK2BRD4CDK4 | |
| SCHEMBL3967294 | 0.89 | DCLK1 (0.62) | TNK2JAK3JAK2BRD4CDK4 | |
| SCHEMBL3971348 | 0.87 | CDK4 (0.57) | TNK2JAK3JAK2BRD4CDK4 | |
| SCHEMBL3967315 | 0.87 | DCLK1 (0.49) | TNK2JAK3JAK2BRD4CDK4 | |
| SCHEMBL3971047 | 0.85 | RPS6KA6 (0.64) | TNK2JAK3JAK2CDK4CCND1 | |
| SCHEMBL3967395 | 0.82 | SYK (0.48) | TNK2JAK3JAK2BRD4CDK4 | |
| SCHEMBL3968472 | 0.81 | CDK4 (0.64) | TNK2JAK3JAK2BRD4CDK4 | |
| SCHEMBL17396455 | 0.80 | CDK4 (0.61) | JAK3JAK2CDK4CCND1CCNT1 | |
| SCHEMBL3973278 | 0.80 | CDK4 (0.46) | TNK2JAK3JAK2CDK4CCND1 | |
| SCHEMBL17396469 | 0.79 | STAT6 (0.58) | TNK2JAK3CDK4CCND1CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | claimed |
| EP-1080092-B1 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2008-07-23 | — | — | EP | claimed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | claimed |
| WO-2023069959-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1080092-B1 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | DOBRUSIN ELLEN MYRA (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | CCNI, CCNH, CCNA1 | TNK2 277/4885JAK3 991/4885JAK2 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.